Abbott Laboratories, of Abbott Park, Ill., saw worldwide medical devices sales rise 5.5% on a reported basis – and 9.5% on an organic basis – in a first quarter that beat the street. The company impressed as it experienced double-digit growth in electrophysiology, heart failure, structural heart and diabetes care.
Columbus, Ohio-based Deep Lens Inc., which focuses on artificial intelligence (AI) to help in clinical trial recruitment, reported that it has closed a $14 million series A financing, led by Northpond Ventures. Also joining were existing investors Rev1 Ventures, Sierra Ventures and Tamarind-Hill Partners. News of the round comes three months after Deep Lens closed its venture capital-led seed equity round, bringing the total raised to $17.5 million.
Medtronic plc, of Dublin, highlighted results of a study that demonstrated a reduction in health care utilization and cost for cancer pain patients using targeted drug delivery (TDD) and conventional medical management (CMM) vs. CMM alone. TDD was delivered by the Medtronic Synchromed II infusion system, which is an implantable pump that delivers medication directly to the fluid around the spinal cord.
